Chemotherapy/chemoradiation vs. R2 surgical debulking vs. palliative care in recurrent rectal cancer 

Dr Luca Sorrentino, Colorectal Surgery Unit, Fondazione IRCCS Istituto Nazionale dei Tumori Milan, Italy presents their article published in Tumori Journal
Outcomes of chemotherapy/chemoradiation vs. R2 surgical debulking vs. palliative care in nonresectable locally recurrent #rectalcancer
Locally recurrent rectal cancer is resected with clear margins in only 50% of cases, and these patients achieve a three-year survival rate of 50%. Outcomes and therapeutic strategies for nonresectable locally recurrent rectal cancer have been much less explored.
The aim of the study was to assess the three-year progression-free survival and the three-year overall survival in locally recurrent rectal cancer patients treated by chemotherapy/chemoradiation only vs. #chemotherapy /chemoradiation and R2 surgical debulking vs. #palliativecare
Learn more at the link
journals.sagep...
#colorectalcancer #gastrointestinal #oncosurgeon #oncology #cancertreatment #cancerresearch